Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sorrento Therapeutics, Inc.
This is a multi-center, randomized, double-blind study designed to investigate the safety, pharmacokinetic (PK) profile and efficacy of a single injection of COVI-AMG in outpatient adults with mild COVID-19 symptoms. Subjects will be followed for approximately 70 days post dosing.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Positive for COVID-19 by an approved antigen test
Mild symptoms consistent with a COVID-19 viral infection
Willing and able to comply with all planned study procedures and be available for all study visits and follow-up as required by the protocol
Willing to follow contraception guidelines
You may not be if
Evidence of moderate COVID-19 per FDA severity categorization
Pregnant or lactating and breast feeding or planning on either during the study
Has a documented infection other than COVID-19
Has received a COVID-19 vaccine
Has participated, or is participating, in a clinical research study evaluating COVID-19 convalescent plasma, monoclonal antibodies (mAbs) against SARS-CoV-2, or intravenous immunoglobulin (IVIG) within 3 months or less than 5 half-lives of the investigational product (whichever is longer) prior to the screening visit
Clareo Health | Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms
